

S0040-4039(96)00607-7

A Short Route for the Construction of the Tetracyclic Ring System of Silicine-Methuenine Alkaloids


M.-Lluïsa Bennisar, Bernat Vidal, Angel Lázaro, Rakesh Kumar, and Joan Bosch

Laboratory of Organic Chemistry, Faculty of Pharmacy, University of Barcelona,
 08028-Barcelona, Spain


Abstract: A general synthetic entry to the tetracyclic ring system of silicine-methuenine alkaloids, involving the partial hydrogenation of dihydropyridines **2** followed by PPSE-induced cyclization of the resulting tetrahydropyridine esters **3**, is reported. Copyright © 1996 Published by Elsevier Science Ltd

The nucleophilic addition of 2-acetylindole enolates to *N*-alkylpyridinium salts bearing an electron-withdrawing substituent at the 3-position leads to 4-[(2-indolylcarbonyl)methyl]-1,4-dihydropyridines **1**, which have proved to be useful intermediates in alkaloid synthesis. Straightforward biomimetic syntheses of ervitsine¹ and the alkaloids of the ervatamine group (19,20-dehydroervatamine, 20-epiervatamine),² the latter by way of a 3,5-diacyl-substituted 1,4-dihydropyridine **2**,³ have been accomplished from dihydropyridines **1** (Scheme 1).

In this letter we further illustrate the potential and flexibility of the above methodology: dihydropyridines **2** also provide a direct access to the tetracyclic ring system of silicine-methuenine alkaloids.⁴ In spite of their apparent structural simplicity, these alkaloids have received little synthetic attention, and 6-oxosilicine⁵ is the only alkaloid of this group synthesized so far.⁶



The conversion of dihydropyridines **2** into the target tetracyclic systems required the partial hydrogenation of the dihydropyridine moiety and the closure of the seven-membered C ring. Both transformations have been satisfactorily accomplished starting from a variety of dihydropyridines **2**, bearing different substitution patterns at the β -position and at the indole nitrogen, as outlined in Scheme 2.



Scheme 2

Hydrogenation of dihydropyridines **2a-f**³ in the presence of platinum led to the corresponding tetrahydropyridines **3a-f**, in which the substituents at the 3- and 4-positions are *cis*, as the exclusive or major products. The best yields were obtained in the 3,5-bis(methoxycarbonyl) series (series **a** and **b**).⁷ As was expected, reduction of the acrylate moiety occurs from dihydropyridines **2c** and **2d** to chemoselectively give tetrahydropyridines **3c**⁸ and **3d**. In these series, over-reduction to the corresponding piperidines **5** was also observed. On the other hand, hydrogenation of dihydropyridine **2e** predominantly gave the vinylogous urethanes **3e**⁹ and **3g** in 55% overall yield, although the corresponding vinylogous amide was also formed to a considerable extent. All these results are shown in Table 1.

Table 1. Catalytic Hydrogenation of Dihydropyridines **2 and Cyclization of Tetrahydropyridines **3**^a**

Dihydropyridine	Tetrahydropyridine % yield	Tetracycle % yield
2a	3a , 80	4a , 30
2b	3b , 60	4b , 40
2c	3c , 30 ^{b,c}	4c , 40
2d	3d , 25 ^b	4d , 25
2e	3e , 25+ 3g , 30 ^{d,e}	--
2f	3f , 45 ^f	4f , 45 ^g

^a All yields are from material purified by column chromatography. All new compounds gave satisfactory spectral, analytical and/or HRMS data. ^b The corresponding piperidines **5** were formed in 15% yield. ^c The *trans* isomer was isolated in 15% yield. ^d This yield increased to 55% when reaction times were longer (48 h). ^e The isomeric vinylogous amide was isolated in 30% yield. ^f Reference 2. ^g Epimeric mixture at C-20.

Table 2. ^{13}C -NMR Chemical Shifts of Tetrahydropyridines **3** and Tetracycles **4a,b**

	C-3	C-5	C-6	C-14	C-15	C-16	C-20	C-21	NMe	Y
3a^c	192.8	145.9	167.7 ^d	44.2	29.7	97.0	41.2	44.6	42.7 32.0	51.8 172.6
3b	191.0	146.3	168.1 ^d	43.6	30.0	96.9	41.0	44.4	42.7	50.7 168.1
3c	193.4	146.1	168.3 ^d	43.1	30.6	98.0	35.9	49.1	42.7 32.1	25.4 31.8 ^e
3d	192.5	146.4	168.6 ^d	42.4	30.7	97.7	35.9	48.8	42.7	25.2 31.5 ^e
3e	192.0	145.9	167.8 ^d	43.6	28.9	97.8	48.5	44.5	42.8 32.1	30.2 209.2
3f	191.4	145.9	167.8 ^d	43.4	28.4	97.7	48.3	44.5	42.7	30.0 209.2
3g^f	195.3	146.7	167.9 ^d	44.6	29.4	98.3	45.8	47.0	42.7 32.3	22.6 66.6
4a	194.2	147.1	183.5	48.0	28.9	107.8	41.4	45.3	43.3 32.6	52.3 171.5
4b^c	192.8	146.4	183.8	46.4	29.4	108.7	42.1	45.2	43.1	52.3 171.6
4c	195.3	146.5	184.5	49.6	29.7	108.9	35.0	46.0	43.0 32.5	24.6 31.7 ^e
4d	193.6	146.7	184.1	43.9	30.5	109.8	35.5	49.7	43.0	24.7 31.6 ^e
4f^g	193.7	146.7	183.9	48.6	28.5	106.5	51.0	45.7	43.3	29.1 206.1

^a Biogenetic numbering as depicted in Scheme 2. ^b In ppm relative to TMS. Measured in CDCl_3 solution at 74.5 MHz. ^c Assignments were aided by HMQC. ^d For the OMe group (average value) 50.5. ^e For the CO_2Me group (average values) 51.5, 173.5. ^f In CD_3COCD_3 solution. ^g Major cis epimer.

The cis relationship between the tetrahydropyridine substituents in **3** is the result of the hydrogen uptake from the less hindered face of the dihydropyridine ring and, as could be determined from their ^1H -NMR spectra,⁷⁻⁹ implies the equatorial disposition of the substituent at the 3-position and the pseudoaxial disposition of the (indolylcarbonyl)methyl group.

Closure of C ring was achieved by treatment of tetrahydropyridines **3** with trimethylsilyl polyphosphate (PPSE). The tetracyclic silicine-methuenine type systems **4**^{10,11} were obtained in acceptable yields (Table 1). It is worth mentioning that in the 3,5-bis(methoxycarbonyl) series cyclization takes place chemoselectively on the α , β -unsaturated ester group.

Some significant ^{13}C -NMR chemical shifts of tetrahydropyridines **3** and tetracycles **4** are given in Table 2.

The results reported here establish a general synthetic entry to the tetracyclic ring system of silicine-methuenine alkaloids that may be applicable to the synthesis of alkaloids of this group.

Acknowledgment. Financial support from the DGICYT, Spain (project PB94-0214) is gratefully acknowledged. R.K. thanks the CICYT (Spain) for providing a postdoctoral fellowship. Thanks are also due to the "Comissionat per a Universitats i Recerca", Generalitat de Catalunya, for Grant SGR95-0428 and for a fellowship to B.V.

REFERENCES AND NOTES

- Bennasar, M.-L.; Vidal, B.; Bosch, J. *J. Am. Chem. Soc.* **1993**, *115*, 5340-5341.
- Bennasar, M.-L.; Vidal, B.; Bosch, J. *J. Org. Chem.* **1996**, in press.
- Bennasar, M.-L.; Vidal, B.; Bosch, J. *J. Org. Chem.* **1995**, *60*, 4280-4286.
- (a) Joule, J. A. In *Indoles, The Monoterpenoid Indole Alkaloids*, Saxton, J. E., Ed. In *The Chemistry of Heterocyclic Compounds*; Weissberger, A., Taylor, E. C., Eds.; Wiley: New York, 1983; Vol. 25, Part 4, pp 232-239. (b) Alvarez, M.; Joule, J. In *Monoterpenoid Indole Alkaloids*, Saxton, J. E., Ed. In *The Chemistry of Heterocyclic Compounds*; Taylor, E. C., Ed.; Wiley: Chichester, 1994; Vol. 25, Supplement to Part 4, pp 234-236.
- Husson, H.-P.; Bannai, K.; Freire, R.; Mompon, B.; Reis, F. A. M. *Tetrahedron* **1978**, *34*, 1363-1368.
- For the synthesis of a model tetracyclic structure, see: Grierson, D. S.; Bettiol, J.-L.; Buck, I.; Husson, H.-P.; Rubiralta, M.; Díez, A. *J. Org. Chem.* **1992**, *57*, 6414-6421.
- 3a**: $^1\text{H-NMR}$ (CDCl_3 , 500 MHz) 2.87 (masked, 1H, 3-H), 2.88 (dd, $J = 14.5, 5.5$ Hz, 1 H, CH_2CO), 2.99 (dd, $J = 14.5, 7.5$ Hz, 1 H, CH_2CO), 3.01 (s, 3H, NMe), 3.16 (ddd, $J = 13.0, 4.5, 1.5$ Hz, 1H, 2- H_{eq}), 3.43 (t, $J = 13.0$ Hz, 1H, 2- H_{ax}), 3.53 and 3.65 (2s, 3H, OMe), 3.83 (m, 1H, 4-H), 4.02 (s, 3 H, NMe), 7.10 (m, 1 H, indole 5-H), 7.35 (m, 4H, indole, 6-H), 7.68 (d, $J = 8$ Hz, 1 H, indole 4-H). Anal. calcd for $\text{C}_{21}\text{H}_{24}\text{N}_2\text{O}_5$: C, 65.61; H, 6.29; N, 7.29. Found: C, 65.60; H, 6.41; N, 7.12.
- 3c**: $^1\text{H-NMR}$ (CDCl_3 , 300 MHz) 1.67 (m, 2H, CH_2), 1.93 (m, 1H, 3-H), 2.45 (m, 2H, $\text{CH}_2\text{CO}_2\text{Me}$), 2.74 (dd, $J = 14.3, 3.0$ Hz, 1H, CH_2CO), 2.95 (m, 3H, CH_2CO , 2-H), 3.00 (s, 3H, NMe), 3.40 (m, 1H, 4-H), 3.42 and 3.65 (2s, 3H, OMe), 4.05 (s, 3H, NMe), 7.15 (m, 1H, indole 5-H), 7.34 and 7.37 (2s, indole 3-H, 6-H), 7.35 (m, 2H, indole 6- and 7-H), 7.69 (dm, $J = 8.0$ Hz, 1H, indole 4-H). HRMS calcd for $\text{C}_{23}\text{H}_{28}\text{N}_2\text{O}_5$ 412.1998, found 412.2017.
- 3e**: $^1\text{H-NMR}$ (CDCl_3 , 300 MHz) 2.36 (s, 3H, MeCO), 2.90 (m, 4H, CH_2CO , 2-H, 3-H), 3.03 (s, 3H, NMe), 3.42 (t, $J = 12.1$ Hz, 1H, 2- H_{ax}), 3.53 (s, 3H, OMe), 3.90 (m, 1H, 4-H), 4.02 (s, 3H, NMe), 7.12 (m, 1H, indole 5-H), 7.21 (s, 1H, 6-H), 7.38 (m, 3H, indole), 7.68 (dm, $J = 8.0$ Hz, 1 H, indole 4-H). Anal. calcd for $\text{C}_{21}\text{H}_{24}\text{N}_2\text{O}_4$: C, 68.46; H, 6.57; N, 7.60. Found: C, 68.47; H, 6.57; N, 7.61.
- 4b**: $^1\text{H-NMR}$ (CDCl_3 , 500 MHz, biogenetic numbering) 2.64 (dd, $J = 17.5, 1.5$ Hz, 1H, 14-H), 2.74 (dd, $J = 17.5, 12.5$ Hz, 1H, 14-H), 3.05 (m, 1H, 20-H), 3.16 (s, 3H, NMe), 3.36 (m, 2H, 21-H), 3.55 (dd, $J = 12.5, 2.7$ Hz, 1H, 15-H), 3.75 (s, 3H, OMe), 7.30 (m, 1H, 10-H), 7.40 (m, 2H, 11- and 12-H), 7.74 (s, 1H, 5-H), 8.55 (d, $J = 8.0$ Hz, 1H, 9-H), 9.50 (br, 1H, NH). Anal. calcd for $\text{C}_{19}\text{H}_{18}\text{N}_2\text{O}_4$: C, 67.45; H, 5.36; N, 8.28. Found: C, 67.56; H, 5.39; N, 8.08.
- 4c**: $^1\text{H-NMR}$ (CDCl_3 , 300 MHz, biogenetic numbering) 1.74 (m, 2H, 19-H), 2.04 (m, 1H, 20-H), 2.36 (m, 2H, 18-H), 2.55 (dd, $J = 18.0, 12.7$ Hz, 1H, 14-H), 2.87 (dd, $J = 18.0, 2.2$ Hz, 1H, 14-H), 3.02 (m, 3H, 15-H, 21-H), 3.10 (s, 3H, NMe), 3.65 (s, 3H, OMe), 3.99 (s, 3H, NMe), 7.28 (m, 1H, 10-H), 7.41 (m, 2H, 11-H, 12-H), 7.12 (s, 1H, 5-H), 8.50 (d, $J = 8.0$ Hz, 1H, 9-H). HRMS calcd for $\text{C}_{22}\text{H}_{24}\text{N}_2\text{O}_4$ 380.1736, found 380.1745.